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The aim of this follow-up study was, to compare the effects of mechanical periodontal
therapy with or without adjunctive amoxicillin and metronidazole on the subgingival
microbiome of smokers with periodontitis using 16S rDNA amplicon next generation
sequencing. Fifty-four periodontitis patients that smoke received either non-surgical
periodontal therapy with adjunctive amoxicillin and metronidazole (n = 27) or with
placebos (n = 27). Subgingival plaque samples were taken before and two months after
therapy. Bacterial genomic DNA was isolated and the V4 hypervariable region of the
bacterial 16S rRNA genes was amplified. Up to 96 libraries were normalized and pooled
for Illumina MiSeq paired-end sequencing with almost fully overlapping 250 base pairs
reads. Exact ribosomal sequence variants (RSVs) were inferred with DADA2. Microbial
diversity and changes on the genus and RSV level were analyzed with non-parametric
tests and a negative binomial regression model, respectively. Before therapy, the
demographic, clinical, and microbial parameters were not significantly different between
the placebo and antibiotic groups. Two months after the therapy, clinical parameters
improved and there was a significantly increased dissimilarity of microbiomes between
the two groups. In the antibiotic group, there was a significant reduction of genera
classified as Porphyromonas, Tannerella, and Treponema, and 22 other genera also
decreased significantly, while Selenomonas, Capnocytophaga, Actinomycetes, and
five other genera significantly increased. In the placebo group, however, there was
not a significant decrease in periodontal pathogens after therapy and only five other
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genera decreased, while Veillonella and nine other genera increased. We conclude that in
periodontitis patients who smoke, microbial shifts occurred two months after periodontal
therapy with either antibiotics or placebo, but genera including periodontal pathogens
decreased significantly only with adjunctive antibiotics.
Keywords: microbiota, smoking, periodontal therapy, systemic antibiotics, 16S rDNA amplicon sequencing
INTRODUCTION
Periodontitis is a highly prevalent, biofilm-associated disease
and the main reason for tooth loss in the elderly population
(Frencken et al., 2017). In a large multi-center study (ABPARO)
a statistically significant benefit of amoxicillin (500mg) and
metronidazole (400mg) as an adjunct to periodontal therapy
was investigated and clinical results were published (Harks et al.,
2015). We recently performed a microbial sub-group analysis
of non-smoking periodontitis patients from the ABPARO
study (Hagenfeld et al., 2018). We showed that the used
antibiotics caused a microbiome shift characterized by the
reduction of the amounts of periodontal pathogens and
increase of commensal bacteria in the subgingival biofilm, 2
months after periodontal therapy. Cigarette use is a major
risk factor for destructive forms of periodontal disease and
profoundly influences the subgingival microbiome, which means
that it is more diverse, pathogen rich, and commensal poor
(Winkelhoff et al., 2001; Shchipkova et al., 2010; Bizzarro
et al., 2013; Moon et al., 2015), even in shallow periodontal
pockets ≤4mm (Haffajee and Socransky, 2001). Re-colonization
with commensals after periodontal therapy is compromised
in smokers, because they maintain a pro-inflammatory host
phenotype (Joshi et al., 2014).
Metronidazole interferes with the nucleic acid synthesis
of bacteria. It has an antimicrobial spectrum against
anaerobic bacteria including the periodontal pathogens
Porphyromonas ginigvalis, Tannerella forsythia, and Treponema
denticola (Loesche et al., 1984). Amoxicillin inhibits the
synthesis of bacterial cell walls and has a synergistic
effect together with metronidazole on the reduction of
Aggregatibacter actinomycetemcomitans that is associated
with aggressive forms of periodontitis (van Winkelhoff
et al., 1989). Currently, there are only a few studies
that have examined the microbial community effects of
adjunctive amoxicillin and metronidazole in the periodontal
treatment of smokers (Matarazzo et al., 2008; Faveri et al.,
2014). Those studies, however, detected only a pre-defined
and limited number of bacteria with the DNA-DNA
checkerboard method. So-called “next-generation sequencing”
allows for a hypothesis-free and unrestricted view on the
microbial dynamics, because no pre-selection of bacteria
is needed.
To date, there has been no next generation sequencing
study that has investigated the microbial dynamics of smokers
after therapy with or without antibiotics. Therefore, the aim
of this study was to compare the effects of mechanical
periodontal therapy with or without adjunctive amoxicillin and
metronidazole on the subgingival microbiome of patients that
smoke and have periodontitis using 16S rDNA amplicon next
generation sequencing.
MATERIALS AND METHODS
Patient Characteristics
Specimens from the ABPARO study—a multicenter randomized,
double-blinded, parallel group, placebo-controlled study
on the effects of adjunctive antibiotics during periodontal
treatment—were used (ISRCTN: 64254080, Clinical Trials.gov
NCT00707369) (Harks et al., 2015). Smokers were defined as
persons self-declared as smokers and having a concentration
of carbon-monoxide (CO) ≥ 7 ppm by using a Smokerlyzer
(Bedfont-Smokerlyzer R©, Bedfont, UK) (Harks et al., 2015). All
smokers received the same mechanical periodontal treatment.
In total, 71 of the 345 per-protocol patients were smokers.
Of those, nine were diagnosed with severe (Stage III) and 62
with moderate periodontitis (Stage II) (Tonetti et al., 2018).
Seven severely and 27 moderately diseased smokers received an
adjunctive placebo, and two severely and 35 moderately diseased
smokers received adjunctive amoxicillin and metronidazole
(500 mg/400mg thrice daily for 7 days). Because of the small
and unbalanced treatment groups of severely diseased smokers,
only the data from the smokers with moderate periodontitis
were included in this study and reported here. To ensure the
best clinically comparable groups at baseline, the 27 smokers
with moderate periodontitis from the placebo group were
matched to 27 of the 35 moderately diseased smokers from
the antibiotic group (Ho et al., 2011). Samples of those 54
smokers were analyzed for the examination time-points before
and 2 months after therapy. Subgingival specimens were taken
from four teeth with periodontitis and a pocket probing depth
of ≥6mm, one in each quadrant, as described previously
(Hagenfeld et al., 2018, 2019). One sterile paper point (ISO45,
Roeko Dental, Langenau, Germany) was inserted for 10 s in
each site and all paper points were removed and pooled in one
sterile collection tube. The sampling sites remained the same
for both sampling timepoints. This study was approved by
the Medical Ethics Committee of the University of Muenster
(ref: 2016-505-f-S).
Library Preparation
Bacterial genomic DNA from the samples of smokers and non-
smokers was isolated and purified using the QiaAmp DNA- Mini
Kit (Qiagen, Hilden, Germany). The integrity and purity of the
DNAwas checked by agarose gel electrophoresis and a Nanodrop
(Thermo Scientific, Silverside, USA) measurement, respectively.
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DNA quantification was performed with a Qubit 2.0 fluorometer
together with the Qubit dsDNA BR Assay Kit (Thermo Fisher,
Waltham, MA, USA). Two PCRs were done with KAPA HiFi
Hot Start DNA Polymerase (Ready Mix, KAPA-Biosystems,
Boston, MA, USA). In the first PCR, universal eubacterial tailed
tag dual index amplification primers with an amplicon size of
291 bp (E. coli-position 515 to 806) were utilized for amplifying
the V4 hypervariable regions of the bacterial 16S rRNA gene
(Klindworth et al., 2013): EMP515f TCGTCGGCAGCGTCAG
ATGTGTATAAGAGACAGGTGYCAGCMGCCGCGGTAA;
806_R GTCTCGTGGGCTCGGAGATGTGTATAAGAGAC
AGGACTACHVGGGTATCTAATCC. The 16S rDNA specific
regions were marked as bold. In the second PCR, sample-
specific “barcode”-primers and adapter sequences were attached
using the Nextera XT Index Kit Version 2 (Illumina, San
Diego, CA, USA) with 96 barcode combinations. Up to 96
libraries were normalized and pooled for an Illumina MiSeq
sequencing run with 250 base-pair paired-end reads using
MiSeq Reagent Kit Version 2 (Illumina). Five negative control
samples contained molecular biology grade water which allowed
for the identification of potential external contamination in
each sequencing run. Additionally, one evenly balanced mock
sample supplemented each run with 23 known species with 24
RSVs to allow for inter-run quality control. The composition of
the mock sample can be found in Supplementary File 1. The
DNA extraction steps for the mock sample were performed as
described earlier with one modification: the DNA isolation for
themock species was performed with Qiagen Genomic Tips 20/G
(Qiagen, Hilden, Germany). All 23 single-species samples were
adjusted to 107 copies of the 16S rRNA operon per organism
per microliter. Afterwards, an even mock sample was created by
combining equal amounts of these dilutions with a total copy
number of 107 16S rRNA operons per microliter resulting in 4.3
× 105 16S rRNA operons per species per microliter.
Sequence Generation, Primer, and Adapter
Removal
lllumina’s MiSeq Control Software v.2.6.2.1 was used to
operate the MiSeq machine. The Real-time Analysis Software
v.1.18.54 performed image analysis, base calling, and quality
score assignment to each base for each cycle. The MiSeq
Reporter Software v.2.6.3 was used for demultiplexing, FastQ
file generation, and adapter removal. Sequencing primers
were removed with Cutadapt v.1.8.1 (Martin, 2011) using
the default setting, that is, a maximum error rate in the
adapter region of 10%. Those trimmed reads were submitted
to the European Nucleotide Archive (http://www.ebi.ac.uk/ena/)
of EMBL European Bioinformatics Institute under the study
accession number PRJEB35812.
Denoising and Merging
The adapter and primer-free FastQ files were further processed
using R v.3.6.1 and RStudio v.1.1.463 (R Development Core
Team, 2017) with DADA2 v.1.12.1 (Callahan et al., 2016). If not
mentioned explicitly below, the default settings (most noticeably,
a zero-mismatch allowed in the overlap region while merging
the forward and reverse reads) were used. First, the forward and
reverse reads were trimmed one base at the 3′-end to remove
the terminal base without the quality score that was attached
during sequencing. Second, the reads were trimmed at the 5′-
end to allow for merging with minimal unpaired bases at both
ends calculated for E. coli (forward reads were trimmed 22 bases,
reverse reads 20 bases). Third, a maximum of two expected errors
per read was allowed to filter out low-quality reads. Finally, the
minimal abundance was set to 10 reads per run for forming the
ribosomal sequence variant (RSV) partitions during denoising.
Taxonomic Labeling and Decontamination
Taxonomic labeling of RSVs was done with a naïve Bayesian
classifier and a SILVA v.128 training set (Pruesse et al., 2007).
Each run was stored using phyloseq v.1.19.1 (McMurdie and
Holmes, 2013) into a single file containing taxonomic labels
and reads for each RSV. The QC-checked sequencing runs were
individually screened for potential external contaminants, using
the decontam package v.1.4.0 (Davis et al., 2018). The combined
prevalence and frequency methods were used with the default
threshold of 0.1 for identifying contaminants. Afterwards, all
single-run phyloseq files weremerged and combined with clinical
and demographic variables into the final phyloseq file. Finally,
prevalence filtering over all the runs was done of RSVs occurring
in only two or less samples to remove spurious ones.
Run and Sample Quality Control
Run quality control was performed after each sequencing run in
two consecutive steps. First, the run-Q30 scores were checked
with the MiSeq Reporter software. Here, the values had to be
above 75% as recommended by the manufacturer (Illumina,
2012). Second, the mock sample was denoised using the DADA2
pipeline and checked with phyloseq. A run was judged of
sufficient quality when 24 found RSVs completely matched the
reference 16S RNA genes of each 23 species from the mock
sample and ≤ 0.5% reads per sample were found without
matching references. Sample quality control was first performed
for all samples after each run and again a second time after the
final phyloseq file with all included runs was created. Samples had
insufficient quality when the rarefaction quality control did not
show saturation or the samples had≤5,000 reads.
Statistical Analysis
For the community level analysis, phyloseq was used to analyze
the bacterial diversity. For alpha diversity, the richness, that is, the
randomly sub-sampled number of observed reads per RSVs in
each sample, was determined. In addition, the Shannon index for
diversity was provided. For beta diversity, a Bray-Curtis distance
matrix was created, and the mean dissimilarity for each patient
was calculated. Fisher’s exact test was used for the intergroup
differences of the categorical variables. For all other continuous
variables, the two-sided Mann–Whitney U-test for intergroup
differences was used. For the changes of the continuous variables
in both groups before and after the treatment, the Wilcoxon
signed-rank test was applied.
The differences in the mean number of randomly subsampled
RSV reads per genus between the antibiotic and placebo before
and after therapy were displayed in a heatmap. For the statistical
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analysis of the differential abundance of single RSVs classified on
genus level, the R package DESeq2 v.1.18.1 (Love et al., 2014)
was used. The model formula contained the treatment-group
(AB, placebo), the timepoint (before, after), and the interaction
term between both groups as fixed effects. The RSVs grouped
per genus that changed significantly in the antibiotic and placebo
groups were displayed in a bubble chart. If one genus included
species associated with periodontal disease or health by the
Socransky group (Socransky et al., 1998), this genus was allocated
to the given complex as described earlier (Hagenfeld et al., 2018).
RESULTS
Demographic, Clinical Parameters Before
and After Therapy and Preprocessing the
Sequencing Output
Before therapy, there were no statistically significant differences
between the placebo and antibiotic groups in all the demographic
and clinical parameters examined (Table 1). After therapy,
clinical parameters improved significantly in both groups
(Supplementary Table 1, Supplementary File 2). All sequencing
runs passed the run quality control as described previously
(Supplementary Table 3). A total of five RSVs were found to be
suspicious for external contaminants and removed. In addition,
645 RSVs had a prevalence in≤2 samples and were also removed,
together with two RSVs not classified as from the bacterial
kingdom. All samples showed a saturation during rarefaction and
had more than 5,000 reads per sample (data not shown).
Microbial Diversity Parameters Before and
After Therapy
Before therapy, there were no statistically significant differences
between the placebo and antibiotic groups in any of the microbial
diversity parameters tested: mean richness (placebo 161.81 ±
TABLE 1 | Clinical and demographic variables for the placebo and antibiotic
groups before therapy.
Placebo
(n = 27)
Antibiotic
(n = 27)
p-value
Sex Female 15 16 p = 1.000
Male 12 11
< 45 11 8 p = 0.5131
Age 45 ≤ 55 13 13
> 55 3 6
Mean and sd 24.48 ± 13.13 21.67 ± 13.38 p = 0.3632
%PD 5mm Median 25.00 19.00
1st, 3rd Quantile 13.00, 35.00 13.00, 26.00
Mean and sd 31.70 ± 14.95 28.04 ± 14.64 p = 0.3677
%Bleeding Median 30.00 30.00
1st, 3rd Quantile 22.50, 39.50 21.50, 35.00
Sex, age, percentage of pocket depths ≥ 5mm, and percentage of sites with bleeding for
the placebo and antibiotic groups. Categorical values were tested for uneven distribution
at baseline with Fisher’s exact test; for continuous variables, the Mann–Whitney U-test
was used.
53.27 sd vs. antibiotic 169.93 ± 57.32 sd, p = 0.595), mean
diversity (placebo 3.84 ± 0.39 vs. antibiotic 3.86 ± 0.41, p =
0.797), and mean dissimilarity (placebo 3.84± 0.39 vs. antibiotic
3.86± 0.41, p= 0.757). After therapy, the dissimilarity increased
significantly in both the placebo (p = 0.034) and the antibiotic
group (p < 0.001). Richness (p = 0.768) and diversity (p =
0.090) were not significantly altered in the placebo group. In
the antibiotic group, however, richness (p = 0.002) and diversity
(p = 0.016) significantly decreased. A detailed table of diversity
parameters can be found in Supplementary Table 2.
Genus Level Abundances, Before, and
After Therapy
We found in total 1060 RSVs that can be assigned to 143
different genera (Supplementary File 3). Before therapy, the
relative number of sub-sampled reads summarized by per genus
was highly similar between the placebo and the antibiotic groups
(Figure 1).
Before therapy, no genus was more dissimilar than 1.0 percent
between antibiotic and placebo. Those RSVs with the highest
differences before therapy were Fusobacterium, Veillonella, and
Prevotella, all below a 0.5 percent difference. The three genera
with the highest relative abundance before therapy were:
Fusobacterium (placebo: 6.0% vs. antibiotic: 5.5%), Veillonella
(placebo: 0.4% vs. antibiotic: 0.8%), and Prevotella (placebo: 1.4%
vs. antibiotic: 1.1%).
After therapy, the microbiomes became more dissimilar
between the placebo and antibiotic groups. The genus with the
highest difference after therapy was Veillonella, which increased
after therapy in both groups and had a relative abundance of
1.1% in the placebo group, compared to 1.9% in the antibiotic
group. Fretibacterium and Porphyromonas decreased less in the
placebo group; they had a relative abundance of 2.0 and 1.9% in
the placebo vs. 0.4 and 0.5% in the antibiotic group, respectively.
In the placebo group, no genus changed more strongly than
one percent of relative abundance. In the antibiotic group, six
genera changed more than one percent. Of those, three genera
(Fretibacterium, Porphyromonas, and Treponema) reduced and
three genera increased more than 1.0% (Veillonella, Rothia,
and Prevotella). In the placebo group, also mainly periodontal
pathogens were reduced and commensals increased after therapy.
However, those changes were in general roughly 0.5–1.5% smaller
than in the antibiotic group.
RSVs Grouped at Genus Level That
Significantly Changed After Therapy
The vast majority (98.8%) of all RSVs were not statistically
different in abundance between the antibiotic and placebo group
before therapy. Those 21 RSVs that were found different in
abundance before therapy belonged to exclusively low-abundant
RSVs with a mean baseline abundance below 1% of each
sample (Supplementary File 4). The abundances of RSVs from
genera including periodontal pathogens like Porphyromonas,
Tannerella, and Treponema decreased significantly only in the
antibiotic group, together with several other species (Figure 2).
RSVs belonging to genera from the commensal bacteria
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FIGURE 1 | (A) Heatmap showing the randomly sub-sampled reads summarized per genus in the placebo and antibiotic groups before and after therapy. The color
codes ranged from 6% to 0% of the summarized reads for each genus. Higher relative numbers of genus reads are colored red, lower numbers are yellow to white,
and dark-blue represents zero values. PL, placebo group; AB, antibiotic group. (B) Heatmap showing randomly sub-sampled reads of the 25 most abundant genera
in the placebo and antibiotic groups before and after therapy. Here, only the 25 most abundant genera before therapy are shown. The color codes ranged from 6 to
0% of the summarized reads for each genus. Higher relative numbers of genus reads are colored red, lower numbers are yellow to white, and dark-blue represents
zero values. PL, placebo group; AB, antibiotic group.
Selenomonas, Capnocytophaga, and Actinomyces significantly
increased after therapy only in the antibiotic group. Two RSVs
belonging to the genus Veillonella increased only in the placebo
group, together with several other RSVs not belonging to
formerly identified commensal species.
DISCUSSION
By using our hypothesis-free next-generation-sequencing
approach, we have provided the first study that examined
in-depth microbial changes in smokers after periodontal therapy
with or without antibiotics. We found a short-term microbiome
shift in the form of a significantly increased beta-diversity
after therapy in both the placebo and antibiotic group. Those
microbial shifts differed markedly between the placebo and
antibiotic group. In the antibiotic group, the microbial shift was
characterized by a strong reduction of alpha-diversity in general,
and especially, periodontal pathogens decreased significantly
while commensals increased. In the placebo group, however,
there was not a significant decrease in alpha-diversity and also
not a significant reduction of periodontal pathogens 2 months
after therapy.
Compared to our previous study with non-smokers
(Hagenfeld et al., 2018), the composition of highly abundant
genera at baseline had a strong resemblance with the smokers in
this study. In both studies, Fusobacterium, Fretibacterium, and
Porphyromonas had the highest baseline abundance. Regarding
RSV changes after therapy, we also had very similar results on the
genus level compared to our study conducted with non-smokers;
RSVs belonging to genera containing periodontal pathogens like
Treponema, Porphyromonas, Tannerella, and Fusobacterium
decreased as in our previous study with non-smokers.
Additionally, in both studies, Fretibacterium and Fillifactor
decreased among several other RSVs classified as genera not
regarded as periodontal pathogens by the fundamental study of
Socransky et al. (1998). Also, in both studies, RSVs that were
classified as genera containing commensal species (Selenomonas,
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 5 May 2020 | Volume 10 | Article 167
Hagenfeld et al. Antibiotic Periodontal Therapy in Smokers
FIGURE 2 | Bubble chart of significant RSV abundance changes after periodontal therapy classified on the genus level. The bubbles represent 98 RSVs, belonging to
31 uniquely named genera (x-axis), that showed statistically significant changes (y-axis) after therapy on a log2 scale. All RSVs unclassified on the genus level are
grouped together (NA). The sizes of the bubbles represent the mean relative RSV abundance over all samples before therapy. Those RSVs with ≥10 log2fold and ≤
−10 log2fold changes were marked as triangles on their respective y-axis section. All RSVs belonging to a genus that includes species previously described by
Socransky are colored according to their complex affiliation.
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Capnocytophaga, and Actinomyces) increased in the antibiotic
group. In the placebo group of non-smokers, however, we did
not find dissimilarity changes, and secondly, only three RSVs
changed significantly in the placebo group of our previous study
with non-smokers.
One previous study (Matarazzo et al., 2008) that used the
DNA-DNA checkerboard method is very comparable to our
study, because they made a direct comparison of two groups
of periodontitis patients who smoked that received either
periodontal therapy with two different kinds of antibiotics
or periodontal therapy without antibiotics. In that study,
patients from the amoxicillin and metronidazole group
underwent similar microbial shifts as in our study. Here, also
periodontal pathogenic species with the genera Porphyromonas,
Tannerella, and Treponema were significantly reduced only
in the antibiotic group, accompanied by an increase of the
species from commensals, that are, Actinomyces, Selenomonas,
and Capnocytophaga.
Another study using the DNA-DNA checkerboard method
compared the use of amoxicillin and metronidazole between
smokers and non-smokers. Here, the smokers treated with
adjunctive antibiotics also had a significant reduction of those
three genera containing periodontal pathogens (Faveri et al.,
2014).
Other groups that examined periodontal therapy without
antibiotics in smokers and non-smokers found a lower reduction
of periodontal pathogens in smokers compared to non-smokers
by using the DNA-DNA checkerboard (Darby et al., 2005; Feres
et al., 2015). These findings were confirmed by our results from
the smokers in the placebo group where the relative numbers
of high-abundant bacteria in general were slightly reduced, but
no RSVs from periodontal pathogens were significantly changed
after therapy.
In contrast to those previous hypothesis-driven studies, the
majority of genera (55%) that were reduced significantly
in our study with patients that smoked and received
adjunctive antibiotics were not regarded as periodontal
pathogens (Socransky et al., 1998). For example, uncultivated
Fretibacterium sp. human oral taxon no. 360 was recently found
as a novel biomarker for periodontitis in a Japanese population
(Khemwong et al., 2019). RSVs from the genus Fretibacterium
were also highly abundant in our population of German smokers
and decreased significantly after periodontal therapy with
antibiotics. Another example is Filifactor alocis that is regarded
as a new emerging periodontal pathogen (Aruni et al., 2014),
or Mogibacterium as a new genus isolated from periodontal
pockets of adult human patients with periodontal disease and
infected root canals (Nakazawa et al., 2000). Both of those genera
were reduced significantly in our study using antibiotics. These
findings point out the importance of those and other previously
unidentified species in the treatment of periodontal disease, as
recently reviewed (Perez-Chaparro et al., 2014).
Our study has also some limitations. A higher taxonomic
resolution down to the species level was not possible with our
250-bp read length. We could not access functional capacities
of the microbiomes as would be possible with a meta-genomic
approach. In addition, the negative binomial regression model
used for the RSV-level changes cannot account for random
patient effects. By using a pooled microbial sample, we cannot
asses site specific differences. We only included moderately
diseased periodontitis patients. A longer follow-up would also
be needed to assess the stability of changes and patterns of
re-colonization after therapy.
CONCLUSIONS
With our hypothesis-free 16S rDNA amplicon next generation
sequencing study with periodontitis patients that smoke, we
found RSVs from genera including periodontal pathogens
exclusively decreased with adjunctive amoxicillin and
metronidazole. Additionally, we expanded the spectrum of
bacteria that changed in short-term after periodontal therapy
in smokers beyond the well-studied periodontal pathogens
and commensals.
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